Objective: The PD-1/PD-L1 signaling pathway contributes to the modulation of the immune system and the maintenance of peripheral immune tolerance. PD-1 and PD-L1 are expressed by various cell types, from T cells to trophoblast cells. The signaling pathway is responsible for maintaining fetomaternal tolerance and the balance between Treg and Th17 cells during pregnancy by regulating the interactions between decidual stromal cells, trophoblast cells, macrophages, and lymphocytes in the decidua. Despite limited studies in recurrent pregnancy loss (RPL), the PD-1/PD-L1 signaling pathway has been shown to have potential importance in immune dysregulation. Therefore, the current review focuses on the effects of the PD-1/PD-L1 signaling pathway on both physiological and pathological pregnancies, including preeclampsia (PE) and RPL, and its potential usage as a promising therapeutic target.
Materials and Method:A literature search was conducted in PubMed, Web of Science, and Scopus to select studies with the keywords: PD-1/PD-L1 signaling pathway, pregnancy immunology, immune tolerance in pregnancy, PD-1/PD-L1 signaling pathway and PE, PD-1/PD-L1 signaling pathway, and RPL. Papers published before January 2024 were selected. Drawing on advances in laboratory science and preclinical medicine, we performed a narrative review of the scientific literature to provide an update on the role of the PD-1/PD-L1 signaling pathway in the immunological response during pregnancy.
Findings and Results:The complexity of the PD-1/PD-L1 signaling pathway during pregnancy and its effects on immunological balance seem to have the potential to open new doors in developing targeted treatment methods and understanding reproductive health outcomes.